Thomas Jonassen
Fortuna: 5 M $ al 31/05/2026
Fortuna: 5 M $ al 31/05/2026
Thomas Jonassen is the founder.
Dr. Jonassen was the founder of Action Pharma A, founded in 2000, holding the title of Chief Scientific Officer.
Dr. Jonassen is also the founder of TXP Pharma GmbH,ResoTher Pharma AS.
Dr. Jonassen is currently an Associate Professor at the University of Copenhagen and the Chief Scientific Officer at SynAct Pharma AB starting in 2024.
Dr. Jonassen holds a doctorate from the University of Copenhagen.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SYNACT PHARMA AB 4,77 % | 19/12/2025 | 2.545.320 ( 4,77 % ) | 5 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SYNACT PHARMA AB | Director Técnico/Científico/I+D | - |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Fundador | - |
| Empresas | Cargo | Fin |
|---|---|---|
TXP Pharma GmbH | Fundador | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Fundador | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
SynAct Pharma AB
SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
TXP Pharma GmbH | |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.